Earnings Release • Feb 16, 2022
Earnings Release
Open in ViewerOpens in native device viewer
Aaron Auld (CEO), Jan-Dirk Henrich (CFO)
Feb. 16, 2022
Copyright © 2022 Exasol. All rights reserved.
This presentation contains future-oriented, forward-looking statements ("Forward- looking Statements"), estimates, opinions, projections and forecasts representing the current assessments and views with respect to anticipated future performance of Exasol AG. These assessments, views and Forward-looking Statements are subject to changes. There are uncertain conditions that are for the most part difficult to predict and are beyond the control of Exasol AG. Exasol AG is not under any obligation to publish any information resulting in changes in framework conditions or to publish revised information.
The information in this presentation as well as the Forward-looking Statements are of preliminary and abbreviated nature and may be subject to updating, revision and amendment, and such information may change materially. Neither Exasol AG nor any of its directors, officers, employees, agents or affiliates undertakes or is under any duty to update this presentation or to correct any inaccuracies in any such information which may become apparent or to provide any additional information. The Forward-looking Statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "aims", "plans", "predicts", "may", "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These Forward-looking Statements include all matters that are not historical facts. They appear in a number of places throughout this presentation and include statements regarding Exasol's intentions, beliefs or current expectations concerning, among other things, Exasol's prospects, growth, strategies, the industry in which it operates and potential or ongoing acquisitions. By their nature, Forward-looking Statements involve significant risks and uncertainties, because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking Statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved.
(preliminary and unaudited)
ARR: 30.5m€ (+29%) Revenue: 27.5m€ (+17%)
Adj. EBITDA: -30.9m€ (2020: -8.7m€)
Liquid Funds: 27.2m€ (2020: 69.5m€)
| New customers since 2021 (examples) | + Strong upsell performance with existing customers (examples) |
|||
|---|---|---|---|---|
| Financial services |
Multinational banking Corp., UK 15bn USD rev./a |
|||
| Multinational insurance Corp., DACH 10bn EUR rev./a |
||||
| Multinational re-insurance Corp., DACH 24bn EUR rev./a |
||||
| Industry | One of the biggest global conglomerates, US 70bn EUR rev./a |
|||
| Healthcare | Multinational Pharma Corp., DACH 18bn EUR rev./a |
80 customers (> 37% of total) increased their business with Exasol in the past 12 months |
50% of customers come from 4 industries / verticals
most ambitious organizations
• Best-in-class in 5 categories (vs 4 previously)
• Remains leader for vendor credibility and customer experience in 5 consecutive years
• Best in class across 20 measures
• 100% customer recommendation rate
• New entrance in Magic Quadrant Report December 2021 as "Niche Player"
• Confirmation of our mission to be the
analytics platform trusted by the world's
• Increased number of top-rankings from 18 to 26 categories vs peer group "Analytical
\$744 \$711* \$85 Price/kQphH in USD (30 TB) Cost per kQphH – lower is better Microsoft SQL Server 2019 OceanBase V3.2 Exasol 7.1
Dresner positioning of Exasol against competition
*Converted from the original currency
by Jan-Dirk Henrich, CFO
Preliminary and unaudited figures
* At comparable FX rates and methodology
Preliminary and unaudited figures
Preliminary and unaudited figures
* At comparable FX rates and methodology
Preliminary and unaudited figures
| 2021 (rep.) |
2020 (rep.) |
Adjustments 2021 |
Adjustments 2020 |
2021 (adj.) |
2020 (adj.) |
|
|---|---|---|---|---|---|---|
| Revenue | 27.5 | 23.6 | - | - | 27.5 | 23.6 |
| Gross Profit |
26.6 | 22.3 | - | - | 22.4 | 22.3 |
| Personnel expenses |
-38.9 | -37.3 | +1.5 | +15.6 | -37.4 | -21.7 |
| Other income / expense |
-12.7 | -15.0 | -7.4 | +5.7 | -20.1 | -9.3 |
| EBITDA | -25.0 | -30.0 | -5.9 | +21.3 | -30.9 | -8.7 |
| EBIT | -27.4 | -34.1 | -5.9 | +21.3 | -33.4 | -12.8 |
| EBT | -27.5 | -34.3 | -5.9 | +21.3 | -33.4 | -13.1 |
| Net income | -28.3 | -34.3 | -5.9 | +21.3 | -34.2 | -13.0 |
Preliminary and unaudited figures
| Q4 2021 | Q4 2020 | Δ% | FY 2021 | FY 2020 | Δ% | |
|---|---|---|---|---|---|---|
| Revenue | 8.1 | 5.9 | 37.2 | 27.5 | 23.6 | 16.6 |
| thereof recurring | 6.7 | 5.3 | 26.7 | 24.8 | 19.0 | 30.3 |
| thereof non-recurring |
1.5 | 0.7 | 120.9 | 2.8 | 4.6 | -40.0 |
| Capitalized own work | 0.5 | 0.5 | 0.0 | 2.3 | 1.9 | 20.2 |
| Gross Profit | 7.7 | 5.3 | 46.4 | 26.6 | 22.3 | 19.5 |
| Gross Profit Margin | 94.8% | 88.9% | - | 96.8% | 94.4% | - |
| Personnel expenses (adj) | -10.5 | -8.7 | 21.0 | -37.4 | -21.7 | 72.4 |
| Other income/expense (adj.) | -5.0 | -3.6 | 40.7 | -20.1 | -9.3 | >100 |
| Total Costs (adj.) | -15.6 | -12.3 | 26.7 | -57.5 | -31.0 | 85.7 |
| EBITDA (adj.) | -7.9 | -7.0 | -11.9 | -30.9 | -8.7 | >-100 |
| EBITDA Margin | -96.9% | -118.8% | - | -112.3% | -36.8% | - |
Preliminary and unaudited figures
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | FY 2021 | FY 2020 | Δ% | |
|---|---|---|---|---|---|---|---|
| Revenue | 6.1 | 6.9 | 6.3 | 8.1 | 27.5 | 23.6 | 16.6 |
| Gross Profit | 6.4 | 6.1 | 6.4 | 7.7 | 26.6 | 22.3 | 19.5 |
| Personnel expenses (adj.) | -6.6 | -10.6 | -9.7 | -10.5 | -37.4 | -21.7 | 72.4 |
| Training and Recruiting | -0.5 | -0.7 | -0.4 | -0.3 | -1.9 | -1.3 | 46.8 |
| Marketing | -2.1 | -3.0 | -3.4 | -2.4 | -10.9 | -3.7 | >100 |
| IT infrastructure | -0.4 | -0.4 | -0.4 | -0.3 | -1.4 | -1.3 | 8.5 |
| Others (adj.) | -1.0 | -1.6 | -1.3 | -2.0 | -5.8 | -3.0 | 93.5 |
| Total Costs (adj.) | -10.7 | -16.2 | -15.1 | -15.6 | -57.5 | -31.0 | >100 |
| EBITDA (adj.) | -4.3 | -10.1 | -8.7 | -7.9 | -30.9 | -8.7 | >-100 |
Preliminary and unaudited figures
Preliminary and unaudited figures
Preliminary and unaudited figures
* incl. short term financial assets
** excl. effects from pre-IPO stock programs and costs of equity increase
by Aaron Auld, CEO and Jan-Dirk Henrich, CFO
Retail / E-Commerce > 50k employees; >14bn EUR sales
Healthcare/Pharma > 3k employees; >6bn EUR sales
Healthcare/Pharma > 100k employees; >17bn EUR sales
Impact
"Exasol's analytics database proved impressive. Primarily due to an excellent price-performance ratio: low cost combined with exceptional performance and integration in Hadoop"
Andreas Bonet – Product Owner
"In addition to the convincing price/performance ration and the outstanding performance of Exasol, we were impressed by the objective approach of the sales team . From the very beginning a very cooperative partnership was apparent."
Stefan Scheller – Manager BI & Analytics
"Exasol inspires us again and again. The system runs extremely smoothly, practically maintains itself, does not degenerate and is always performant - a real quantum leap from the previous database system."
Thomas Lober, Director CoE Business Intelligence
SaaS; cost elasticity on all platforms; added automation capabilities; added connectivity
internal processes; focus on
development; performance
management
complexity reduction
| 2021 | 2022 | 2023-25 | |||||
|---|---|---|---|---|---|---|---|
| ARR/AAC* | 30.5 m€ | 38.5 to 40.0 m€ (at constant currency) |
• 100m EUR ARR/AAC* in the course of 2025 without further equity injection |
||||
| Adj. EBITDA** | -30.9 m€ | -14 to -16 m€ | • Stable growth in 2022/23 with acceleration in 2024/25 |
||||
| Liquid Funds (year end) |
27.2 m€ | 10 to 12 m€ | • Operating cashflow break even in the course of 2023 |
||||
| Incl. 2.7 m€ of XO cash-out for pre IPO stock programs Average Annual Revenue (Subscriptions) / Average Annual Consumption (Consumption based pricing) * Excluding effects from pre IPO stock programs 27 |
Copyright © 2021 Exasol. All rights reserved.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.